Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VACdxr +/- ImmTher in High Risk Ewing's Sarcoma
NCT00038142Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 1997
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Disaccharide tripeptide glycerol dipalmitoyl in Ewing sarcoma (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Disease-free Survival at 2 years. Started Nov 1997; status: terminated.
02
Drugs
Disaccharide tripeptide glycerol dipalmitoyl
03
Conditions
Ewing sarcoma
Beyond the preview
Go deeper on NCT00038142.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00038142.